Literature DB >> 19198809

Comparison of the developmental effects of 5-methoxy-N,N-diisopropyltryptamine (Foxy) to (+/-)-3,4-methylenedioxymethamphetamine (ecstasy) in rats.

Matthew R Skelton1, Tori L Schaefer, Nicole R Herring, Curtis E Grace, Charles V Vorhees, Michael T Williams.   

Abstract

RATIONALE: We have previously shown that (+/-)-3,4-methylenedioxymethamphetamine (MDMA) treatment from postnatal days (P)11 to P20 leads to learning and memory deficits when the animals are tested as adults. Recently, the club drug 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT) has gained popularity.
OBJECTIVE: Due to the similarities between MDMA and 5-MeO-DIPT and the substitution of 5-MeO-DIPT for MDMA, the purpose of this study was to compare the developmental effects of these drugs.
METHODS: Within a litter, animals were treated from P11 to P20 with either MDMA, 5-MeO-DIPT, or saline.
RESULTS: MDMA-treated animals showed increased anxiety in a measure of defensive marble burying, as well as deficits in spatial and path integration learning. 5-MeO-DIPT-treated animals showed spatial learning deficits; however, there were no deficits observed in spatial memory or path integration learning. 5-MeO-DIPT-treated animals also showed hyperactivity in response to a challenge dose of methamphetamine.
CONCLUSIONS: The results show that treatment with either 5-MeO-DIPT or MDMA during development results in cognitive deficits and other behavioral changes but the pattern of effects is distinct for each drug.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19198809      PMCID: PMC2888297          DOI: 10.1007/s00213-009-1459-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  44 in total

Review 1.  Path integration in mammals.

Authors:  Ariane S Etienne; Kathryn J Jeffery
Journal:  Hippocampus       Date:  2004       Impact factor: 3.899

Review 2.  Maturation of the adrenocortical stress response: neuroendocrine control mechanisms and the stress hyporesponsive period.

Authors:  R M Sapolsky; M J Meaney
Journal:  Brain Res       Date:  1986-03       Impact factor: 3.252

3.  Alterations in body temperature, corticosterone, and behavior following the administration of 5-methoxy-diisopropyltryptamine ('foxy') to adult rats: a new drug of abuse.

Authors:  Michael T Williams; Nicole R Herring; Tori L Schaefer; Matthew R Skelton; Nicholas G Campbell; Jack W Lipton; Anne E McCrea; Charles V Vorhees
Journal:  Neuropsychopharmacology       Date:  2006-10-18       Impact factor: 7.853

4.  Evaluation of marble-burying behavior as a model of anxiety.

Authors:  K Njung'e; S L Handley
Journal:  Pharmacol Biochem Behav       Date:  1991-01       Impact factor: 3.533

5.  Maze learning in rats: a comparison of performance in two water mazes in progeny prenatally exposed to different doses of phenytoin.

Authors:  C V Vorhees
Journal:  Neurotoxicol Teratol       Date:  1987 May-Jun       Impact factor: 3.763

6.  Exposure to 3,4-methylenedioxymethamphetamine (MDMA) on postnatal days 11-20 induces reference but not working memory deficits in the Morris water maze in rats: implications of prior learning.

Authors:  Charles V Vorhees; Tracy M Reed; Matthew R Skelton; Michael T Williams
Journal:  Int J Dev Neurosci       Date:  2004 Aug-Oct       Impact factor: 2.457

Review 7.  The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Authors:  A Richard Green; Annis O Mechan; J Martin Elliott; Esther O'Shea; M Isabel Colado
Journal:  Pharmacol Rev       Date:  2003-07-17       Impact factor: 25.468

8.  Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2004-09-29

9.  Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine.

Authors:  J F Nash; H Y Meltzer; G A Gudelsky
Journal:  J Pharmacol Exp Ther       Date:  1988-06       Impact factor: 4.030

Review 10.  Dopamine phenotype and behaviour in animal models: in relation to attention deficit hyperactivity disorder.

Authors:  Davide Viggiano; Lucia A Ruocco; Adolfo G Sadile
Journal:  Neurosci Biobehav Rev       Date:  2003-11       Impact factor: 8.989

View more
  11 in total

1.  Electroencephalographic and convulsive effects of binge doses of (+)-methamphetamine, 5-methoxydiisopropyltryptamine, and (±)-3,4-methylenedioxymethamphetamine in rats.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Katherine D Holland; Charles V Vorhees; Michael T Williams
Journal:  Open Neuropsychopharmacol J       Date:  2012

2.  Dopamine depletion in either the dorsomedial or dorsolateral striatum impairs egocentric Cincinnati water maze performance while sparing allocentric Morris water maze learning.

Authors:  Amanda A Braun; Robyn M Amos-Kroohs; Arnold Gutierrez; Kerstin H Lundgren; Kim B Seroogy; Matthew R Skelton; Charles V Vorhees; Michael T Williams
Journal:  Neurobiol Learn Mem       Date:  2014-11-13       Impact factor: 2.877

3.  Distinct periods of developmental sensitivity to the effects of 3,4-(±)-methylenedioxymethamphetamine (MDMA) on behaviour and monoamines in rats.

Authors:  Matthew R Skelton; Devon L Graham; Tori L Schaefer; Curtis E Grace; Amanda A Braun; Lindsey N Burns; Robyn M Amos-Kroohs; Michael T Williams; Charles V Vorhees
Journal:  Int J Neuropsychopharmacol       Date:  2011-06-28       Impact factor: 5.176

4.  Impairment of cognitive flexibility in type 2 diabetic db/db mice.

Authors:  Leonid M Yermakov; Ryan B Griggs; Domenica E Drouet; Chiho Sugimoto; Michael T Williams; Charles V Vorhees; Keiichiro Susuki
Journal:  Behav Brain Res       Date:  2019-05-26       Impact factor: 3.332

Review 5.  Cincinnati water maze: A review of the development, methods, and evidence as a test of egocentric learning and memory.

Authors:  Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2016-08-18       Impact factor: 3.763

6.  Glucose and corticosterone changes in developing and adult rats following exposure to (+/-)-3,4-methylendioxymethamphetamine or 5-methoxydiisopropyltryptamine.

Authors:  Devon L Graham; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams
Journal:  Neurotoxicol Teratol       Date:  2009-09-06       Impact factor: 3.763

7.  Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA.

Authors:  Tori L Schaefer; Curtis E Grace; Amanda A Braun; Robyn M Amos-Kroohs; Devon L Graham; Matthew R Skelton; Michael T Williams; Charles V Vorhees
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-11       Impact factor: 5.176

8.  Neonatal citalopram treatment inhibits the 5-HT depleting effects of MDMA exposure in rats.

Authors:  Tori L Schaefer; Curtis E Grace; Matthew R Skelton; Devon L Graham; Gary A Gudelsky; Charles V Vorhees; Michael T Williams
Journal:  ACS Chem Neurosci       Date:  2011-10-21       Impact factor: 4.418

9.  Dual actions of 5-MeO-DIPT at the serotonin transporter and serotonin 5-HT1A receptor in the mouse striatum and prefrontal cortex.

Authors:  Yoko Hagino; Frank Scott Hall; George R Uhl; Ichiro Sora; Kazutaka Ikeda
Journal:  Neuropsychopharmacol Rep       Date:  2021-02-06

10.  A Systematic Review of the MDMA Model to Address Social Impairment in Autism.

Authors:  Devahuti Chaliha; John C Mamo; Matthew Albrecht; Virginie Lam; Ryu Takechi; Mauro Vaccarezza
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.